Viewing StudyNCT03768531



Ignite Creation Date: 2024-05-06 @ 12:27 PM
Last Modification Date: 2024-10-26 @ 12:59 PM
Study NCT ID: NCT03768531
Status: WITHDRAWN
Last Update Posted: 2020-04-13
First Post: 2018-12-05

Brief Title: Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions & Keywords Data

Conditions:
Name
Resectable Biliary Tract Cancer
Keywords:
Name View
Nivolumab View
Cabiralizumab View
Immunotherapy View
Anti-PD-1 View
Anti-CSF-1R View
Biliary tract cancers BTC View
Neoadjuvant chemotherapy View
Adjuvant chemotherapy View
Tumor microenvironment View